BARNEY PARSON: Open Payments
NPI 1730603689 · GLOUCESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,485 in 102 payments from 15 companies in 2025. Trend: 2023 $1,116 · 2024 $2,192 · 2025 $2,485
Food & beverage: $2,482Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $810 |
| E.R. Squibb & Sons, L.L.C. | 16 | $391 |
| Neurocrine BioSciences, Inc. | 14 | $259 |
| Axsome Therapeutics, Inc. | 6 | $215 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Alkermes, Inc. | 8 | $140 |
| ABBVIE INC. | 9 | $140 |
| Vanda Pharmaceuticals Inc. | 5 | $126 |
| Collegium Pharmaceutical, Inc. | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
Products named: CAPLYTA, COBENFY, INGREZZA, Auvelity, VRAYLAR, ARISTADA, FANAPT, REXULTI.
Industry payments across VA — which companies pay providers there.
